Chapter title |
CDDO and Its Role in Chronic Diseases
|
---|---|
Chapter number | 13 |
Book title |
Drug Discovery from Mother Nature
|
Published in |
Advances in experimental medicine and biology, October 2016
|
DOI | 10.1007/978-3-319-41342-6_13 |
Pubmed ID | |
Book ISBNs |
978-3-31-941341-9, 978-3-31-941342-6
|
Authors |
Bryan J. Mathis, Taixing Cui, Mathis, Bryan J., Cui, Taixing |
Editors |
Subash Chandra Gupta, Sahdeo Prasad, Bharat B. Aggarwal |
Abstract |
There has been a continued interest in translational research focused on both natural products and manipulation of functional groups on these compounds to create novel derivatives with higher desired activities. Oleanolic acid, a component of traditional Chinese medicine used in hepatitis therapy, was modified by chemical processes to form 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO). This modification increased anti-inflammatory activity significantly and additional functional groups on the CDDO backbone have shown promise in treating conditions ranging from kidney disease to obesity to diabetes. CDDO's therapeutic effect is due to its upregulation of the master antioxidant transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2) through conformational change of Nrf2-repressing, Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1) and multiple animal and human studies have verified subsequent activation of Nrf2-controlled antioxidant genes via upstream Antioxidant Response Element (ARE) regions. At the present time, positive results have been obtained in the laboratory and clinical trials with CDDO derivatives treating conditions such as lung injury, inflammation and chronic kidney disease. However, clinical trials for cancer and cardiovascular disease have not shown equally positive results and further exploration of CDDO and its derivatives is needed to put these shortcomings into context for the purpose of future therapeutic modalities. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 22 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 36% |
Researcher | 2 | 9% |
Student > Bachelor | 2 | 9% |
Other | 1 | 5% |
Student > Master | 1 | 5% |
Other | 1 | 5% |
Unknown | 7 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
Biochemistry, Genetics and Molecular Biology | 3 | 14% |
Medicine and Dentistry | 3 | 14% |
Nursing and Health Professions | 2 | 9% |
Computer Science | 1 | 5% |
Other | 3 | 14% |
Unknown | 7 | 32% |